Retatrutide should not be stacked with other GLP-1 or GIP receptor agonists (Semaglutide, Tirzepatide) as it already activates multiple pathways and stacking increases hypoglycemia and nausea risks. However, it can be safely combined with BPC-157 for gut health support during weight loss. The
FDA safety database reports increased adverse events when combining multiple incretin mimetics.